🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients

RecruitingNAAges 18 Years - 90 YearsAllUniversity Hospital, Montpellier
NCT02813642 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To evaluate the relationships between bone mineral markers levels at dialysis start and vascular calcification progression during a 2 year follow up

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient who has signed the written consent form * Patient with chronic renal failure starting dialysis therapy Exclusion Criteria: * Pregnancy * Patient with chronic renal failure not yet on dialysis therapy
💊

What it tests

  • Plasma osteoprotegerin level
  • Plasma fibroblast growth factor 23 level
  • Vascular calcification score
📍

Where

5 sites
Centre Hémodialyse du Lez
Castelnau-le-Lez, France
AIDER
Montpellier, France
CHU Montpellier, Nephrology department
Montpellier, France
CH Nimes, Nephrology department
Nîmes, France
CH Perpignan, Nephrology department
Perpignan, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy